

# One-Pot Synthesis of Ginsenoside Rh2 and Bioactive Unnatural Ginsenoside by Coupling Promiscuous Glycosyltransferase from *Bacillus subtilis* 168 to Sucrose Synthase

Longhai Dai,<sup>†,⊥</sup><sup>®</sup> Can Liu,<sup>‡,⊥</sup> Jiao Li,<sup>†,#</sup> Caixia Dong,<sup>§</sup><sup>®</sup> Jiangang Yang,<sup>†</sup><sup>®</sup> Zhubo Dai,<sup>†</sup> Xueli Zhang,<sup>\*,†</sup> and Yuanxia Sun<sup>\*,†</sup>

<sup>†</sup>National Engineering Laboratory for Industrial Enzymes, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China

<sup>‡</sup>Key Laboratory of Urban Agriculture (North) of Ministry of Agriculture, Beijing University of Agriculture, Beijing, China

<sup>#</sup>University of Chinese Academy of Sciences, Beijing 100049, China

<sup>§</sup>Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnosis, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China

**Supporting Information** 

**ABSTRACT:** Ginsenosides, the major effective ingredients of *Panax ginseng*, exhibit various biological properties. UDPglycosyltransferase (UGT)-mediated glycosylation is the last biosynthetic step of ginsenosides and contributes to their immense structural and functional diversity. In this study, UGT Bs-YjiC from *Bacillus subtilis* 168 was demonstrated to transfer a glucosyl moiety to the free C3-OH and C12-OH of protopanaxadiol (PPD) and PPD-type ginsenosides to synthesize natural and unnatural ginsenosides. In vitro assays showed that unnatural ginsenoside F12 (3-*O*- $\beta$ -D-glucopyranosyl-12-*O*- $\beta$ -Dglucopyranosyl-20(*S*)-protopanaxadiol) exhibited remarkable activity against diverse human cancer cell lines. A one-pot reaction by coupling Bs-YjiC to sucrose synthase (SuSy) was performed to regenerate UDP-glucose from sucrose and UDP. With PPD as the aglycon, an unprecedented high yield of ginsenosides F12 (3.98 g L<sup>-1</sup>) and Rh2 (0.20 g L<sup>-1</sup>) was obtained by optimizing the conversion conditions. This study provides an efficient approach for the biosynthesis of ginsenosides using a UGT-SuSy cascade reaction.

**KEYWORDS:** microbial UDP-glycosyltransferase, glycosylation, protopanaxadiol, unnatural ginsenosides, sucrose synthase, UDP-glucose recycle

# INTRODUCTION

Ginseng, the roots and rhizomes of *Panax ginseng* C. A Meyer, is a well-known and highly valuable medicinal and dietary plant.<sup>1</sup> This perennial herb has been used to enhance immunity, reduce fatigue, prevent aging, and provide nutrition in eastern Asia for more than 2000 years.<sup>2–4</sup> Ginsenosies are the major pharmacologically active components of ginseng.<sup>5</sup> These natural products form a group of glycosylated triterpene saponins that exhibit various pharmacological effects, such as anticancer, antitumor, antistress, antiaging, anti-inflammatory, and immune-system-enhancing activities.<sup>6–9</sup>

Protopanaxadiol (PPD)-type ginsenosides represent one of the two major groups of ginsenosides with a structure consisting of a PPD skeleton and one or more sugar moieties attached to the C3-OH and/or C20-OH of PPD by  $\beta$ glycosidic linkage.<sup>10</sup> Glycosylation mediated by UDP-glycosyltransferase (UGT), the last biosynthetic step of PPD-type ginsenosides, contributes to their immense structural and functional diversity. Most of the key genes involved in the biosynthetic pathway of PPD-type ginsenosides have currently been functionally characterized; an engineered PPD-producing yeast that can accumulate high amounts of PPD has been constructed in our previous study.<sup>11–13</sup> Diverse natural and unnatural PPD-type ginsenosides, including ginsenosides CK, Rh2, F2, Rg3, Rd, and  $3-O-\beta$ -D-glucopyranosyl-12- $O-\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol, have been biosynthesized through the introduction of an engineered PPDproducing pathway and ginseng or microbial UGTs into yeast cell factories; <sup>10,14–17</sup> however, the titers of PPD-type ginsenosides (ca. 9–300 mg L<sup>-1</sup>) produced by yeast cell factories are still considerably low due to the poor catalytic ability of UGTs, the synthetic ability of yeast cells, and the inhibitory effects of the synthesized ginsenosides.

The chemical approach for glycosylation of PPD to synthesize PPD-type ginsenosides is fairly complicated by disadvantages, such as poor stereopecificity, side reactions, low efficiency, and environmental pollution.<sup>18</sup> Although these disadvantages can be alleviated by in vitro enzymatic glycosylation using effective UGTs, UGT-catalyzed glycosylation of PPD requires the costly UDP-glucose (UDPG) as a glucosyl donor, thereby restricting the practical applications of UGTs.<sup>19</sup> Sucrose synthase (SuSy) is a versatile biocatalyst that can efficiently convert cheap sucrose and UDP into UDPG and fructose.<sup>20,21</sup> Furthermore, the coupling of SuSy and UGT in a

Received: January 31, 2018 Accepted: February 27, 2018 Published: February 27, 2018 one-pot reaction can create a UDP recycle, which could instantly regenerate UDPG in the presence of a catalytic amount of UDP, thereby making sucrose the expedient glycosyl donor for the glycosylation of natural products.<sup>22,23</sup>

Compared with plant UGTs, some naturally occurring microbial UGTs show high aglycon promiscuity, poor regiospecificity, and high catalytic proficiency.<sup>24-28</sup> Additionally, microbe-derived UGTs are easier to highly express in the engineered bacteria than plant UGTs.<sup>29</sup> Thus, microbial UGTs are promising biocatalysts for the in vitro semibiosynthesis of ginsenosides or even novel bioactive ginsenosides. Bs-YjiC from Bacillus subtilis 168 is a promiscuous UGT toward a considerable number of structurally diverse compounds.<sup>30</sup> Bs-YiC can also transfer a glucosyl moiety to the free C3-OH, C6-OH, and C12-OH of protopanaxatriol (PPT) to synthesize natural and unnatural PPT-type ginsenosides.<sup>31</sup> In the present study, the regio- and stereospecificity of Bs-YjiC toward PPD and PPD-type ginsenosides was elucidated by analyzing the glycosylated products using high-performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS) and NMR spectra. Furthermore, a one-pot reaction by coupling Bs-YjiC to SuSy from Arabidopsis thaliana (AtSuSy) was established and applied to synthesize PPD-type ginsenosides by using PPD and sucrose as the aglycon and sugar donor, respectively.

## MATERIALS AND METHODS

**Strains and Chemicals.** Authentic PPD and PPD-type ginsenosides were purchased from Chengdu Biopurify Phytochemicals Ltd. (Chengdu, Sichuan, China) and dissolved in dimethyl sulfoxide (DMSO) for use. UDP-glucose (UDPG), UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-galactose (UDP-Gal), and UDP-glucuronic acid (UDP-GlcA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). *Escherichia coli* strains were incubated at 37 °C in Luria–Bertani (LB) medium (5 g L<sup>-1</sup> yeast extract, 10 g L<sup>-1</sup> NaCl, and 10 g L<sup>-1</sup> tryptone) with 100 mg L<sup>-1</sup> ampicillin or 50 mg L<sup>-1</sup> kanamycin.

**Preparation of Recombinant Enzymes.** The coding regions of *Bs-YjiC* (NP\_389104) and *AtSuSy* (NM\_001036838) were amplified from the genomic DNA of *B. subtilis* 168 and cDNA of *A. thaliana*, respectively. *Bs-YjiC* and *AtSuSy* were inserted into the *Bam*HI and *SaII* sites of vector pET28a and *NcoI* and *XhoI* sites of vector pET32a to construct the plasmids pET28a-Bs-YjiC and pET32a-AtSuSy, respectively. For the preparation of recombinant proteins, pET28a-Bs-YjiC and pET32a-AtSuSy were transformed into *E. coli* BL21 (DE3). The recombinant *E. coli* BL21 (DE3) strains were cultured at 37 °C and 200 rpm in an LB medium until the absorbance (OD<sub>600</sub>) reached 0.6–0.8. Isopropyl-β-D-thiogalactopyranoside was added to the medium to a final concentration of 0.2 mM, and the recombinant *E. coli* BL21 (DE3) strains were further incubated at 16 °C for approximately 16–18 h.

Recombinant *E. coli* BL21 (DE3) strains were harvested by centrifugation, resuspended in a lysis buffer (25 mM imidazole, 50 mM Tris-HCl, pH 7.5, and 500 mM NaCl), and disrupted using a French press. The cell extracts were centrifuged at 20000g for 1 h. The supernatants containing the target proteins were loaded onto a nickel–nitrilotriacetic acid–agarose column connected to an AKTA Purifier system (GE Healthcare, Piscataway, NJ, USA) and purified using a 25–200 mM imidazole gradient.

**Enzyme Activity Assays.** Enzymatic assays (0.3 mL) of Bs-YjiC toward PPD or PPD-type ginsenosides were conducted with 1 mM PPD or PPD-type ginsenosides, 5 mM UDPG, UDP-GlcNAc, UDP-Gal, or UDP-GlcA, 50 mM Tris-HCl (pH 8.0), 10 mM MgCl<sub>2</sub>, and 5  $\mu$ g of purified Bs-YjiC for 0.5 h at 40 °C. The reactions were terminated by adding equal volumes of methanol. The reactants were subsequently centrifuged at 10000g for 5 min, filtered through a 0.22  $\mu$ m filter, and directly analyzed by HPLC or HPLC-ESI-MS. A single

unit of enzyme activity was defined as the amount of Bs-YjiC that glycosylated 1  $\mu$ mol of PPD per minute.

Enzymatic assays of AtSuSy were conducted in a 0.3 mL volume containing 0.5 mM UDP, 300 mM sucrose, 50 mM Tris-HCl (pH 7.5), and various amounts of purified AtSuSy for 30 min at 40 °C. AtSuSy activity was measured by determining the amount of fructose released from sucrose and analyzed using the bicinchoninic acid method.<sup>31</sup> A single unit of enzymatic activity was defined as the amount of enzyme that released 1  $\mu$ mol of fructose from sucrose per min.

**Kinetic Analysis of Bs-YjiC.** Kinetic studies (300  $\mu$ L) of Bs-YjiC toward PPD and ginsenoside Rh2 were conducted with purified Bs-YjiC (2  $\mu$ g for PPD and 0.5  $\mu$ g for ginsenoside Rh2), 50 mM Tris-HCl (pH 8.0), 10 mM MgCl<sub>2</sub>, 10 mM UDPG, and varying concentrations of PPD or ginsenoside Rh2 (50–800  $\mu$ M). The reactions were incubated at 40 °C for 20 min and terminated by adding an equal volume of methanol. All the subsequent steps were performed as described above. The kinetic parameters were calculated by nonlinear regression analysis using GraphPad Prism 5.0 software. The  $k_{cat}$  values were calculated using the predicted molecular mass of 4.5 × 10<sup>4</sup> g mol<sup>-1</sup> for Bs-YjiC.

Optimizing the Conditions for the Bs-YjiC/AtSuSy Cascade Reaction. Standard Bs-YjiC/AtSuSy cascade reactions containing 1 mM PPD, 0.5 mM UDP, 50 mM Tris-HCl (pH 7.5), 500 mM sucrose, 10% DMSO (v/v), 160 mU mL<sup>-1</sup> Bs-YjiC, and 200 mU mL<sup>-1</sup> AtSuSy were incubated at 35 °C for 30 min. The optimal pH was determined using 50 mM Na<sub>2</sub>HPO<sub>4</sub>–NaH<sub>2</sub>PO<sub>4</sub> (pH 6.5–7.5) and 50 mM Tris-HCl buffer (pH 7.5–8.5). The optimal temperature was determined ranging from 25 to 45 °C. The optimal concentrations of DMSO, UDP, sucrose, and PPD were individually obtained using different concentrations of DMSO (0–20%), UDP (0.05–0.3 mM), sucrose (0.2–1 M), and PPD (0.5–2 mM) in the standard assay. The optimal ratio of Bs-YjiC and AtSuSy was determined by adding various ratios of Bs-YjiC and AtSuSy in the standard assay.

Fed-Batch Synthesis of Ginsenosides Rh2 and F12 by the Bs-YjiC/AtSuSy Cascade Reaction. The reaction mixtures (10 mL) contained 1 mM PPD, 0.2 mM UDP, 50 mM Tris-HCl (pH 8.0), 0.4 M sucrose, 5% DMSO, 160 mU mL<sup>-1</sup> Bs-YjiC, and 200 mU mL<sup>-1</sup> AtSuSy. The reaction was performed at 40 °C and 150 rpm. In addition, 50  $\mu$ L of reactant was collected and quenched by adding an equal volume of methanol. After centrifugation at 12000g for 10 min, the supernatant was filtered through 0.22  $\mu$ m filters and analyzed by HPLC. A 50  $\mu$ L amount of PPD (200 mM) was periodically added to the reaction mixtures at 1, 2, 4, 6, and 8 h. Fresh enzymes (160 mU mL<sup>-1</sup> Bs-YjiC and 200 mU mL<sup>-1</sup> AtSuSy) were added at 6 h.

HPLC and HPLC-ESI-MS Analysis of the Glycosylated Products. HPLC and HPLC-ESI-MS analyses of the reactants were conducted according to our previous study with some minor changes.<sup>32</sup> The reactants (20  $\mu$ L) were subjected to an XB-C18 column (4.6 × 250 mm, 5  $\mu$ m particles, Welch, Shanghai, China) with a 1 mL/min flow rate and 203 nm UV wavelength. The column was eluted with solvents A (water with 0.1% formic acid) and B (acetonitrile with 0.1% formic acid) using a gradient program of 25–85% B in 0–25 min and 85% B in 25–45 min. The electrospray ionization (ESI) probe was operated in a positive ion mode.

**Structural Analysis of the Glycosylated Products.** For the structural analysis of ginsenosides Rh2 and F12, the Bs-YjiC/AtSuSy cascade reaction (200 mL) was prepared as described above. The reaction was terminated by adding an equal volume of methanol. The reaction mixtures were subsequently concentrated under reduced pressure distillation and resuspended in chromatographic methanol (15 mL). After centrifugation at 10000g for 10 min and filtration through a 0.22  $\mu$ m filter, the glycosylated products were purified using an Agilent 1200 preparative HPLC system coupled with a reverse-phase Ultimate C18 column (21.2 × 250 mm, 5  $\mu$ m particles, Welch, Shanghai, China). The purified products were dissolved in DMSO-*d*<sub>6</sub> or methanol-*d*<sub>4</sub>. 1D NMR (<sup>1</sup>H NMR and <sup>13</sup>C NMR) and 2D NMR spectra (heteronuclear multiple-bond correlation spectroscopy [HMBC], heteronuclear singular quantum correlation [HSQC], and



Figure 1. Proposed glycosylation patterns of Bs-YjiC toward PPD and PPD-type ginsenosides. The solid arrows indicated that the synthesized ginsenosides were confirmed by NMR spectra; the dotted arrows signified proposed glycosylation steps.

homonuclear correlation spectroscopy [COSY]) were obtained using a Bruker DMX-600 NMR spectrometer.

**Cell Viability Assays.** Cell viability assays of unnatural ginsenoside F12 were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay with ginsenosides Rh2 and Rg3 as the positive controls.<sup>33</sup> Cancer cells were seeded at a density of  $1.0 \times 10^4$  cells mL<sup>-1</sup> into a 96-well plate in triplicate. After incubation for 24 h, the cells were treated with different concentrations of ginsenoside Rh2, F12, or Rg3 for 72 h. After incubation, 15  $\mu$ L of MTT solution (5 mg mL<sup>-1</sup>) was added to each well, and the cells were incubated for another 4 h. The growth medium was removed, and 150  $\mu$ L of DMSO was added. The absorbance value of the resulting reaction solution was measured spectrophotometrically at 570 nm using an ELISA reader.

# RESULTS AND DISCUSSION

**Glycosylation of PPD with Bs-YjiC.** Bs-YjiC was heterologously expressed in *E. coli* BL21 (DE3) as an Nterminal His<sub>6</sub>-tagged protein. Notably, Bs-YjiC was expressed mainly as a soluble protein within 16–37 °C (Figure S1). The expression level of Bs-YjiC was approximately 600 mg L<sup>-1</sup> culture medium, which was much higher than those of ginseng UGTs involved in the biosynthesis of ginsenosides from previous studies.  $^{15,16}\,$ 

PPD is the common triterpene skeleton of PPD-type ginsenosides (Figure 1). Therefore, PPD was selected as a probe for the in vitro glycosylation of PPD-type ginsenosides with UDPG as the sugar donor. Two new products (1 and 2) from the Bs-YjiC-catalyzed reaction were identified by HPLC, whereas no new products were detected in the control reaction using the total lysate from induced E. coli BL21 (DE3) that expressed an empty vector (Figure 2A). Further mass analysis of product 1 ( $[M + H]^+ m/z^+ \sim 623.4497]^+$ ,  $[M + H - H_2O]^+$  $m/z^+ \sim 605.4417$ ]<sup>+</sup>, and [M + H - 2H<sub>2</sub>O]<sup>+</sup>  $m/z^+ \sim 587.4311$ ]<sup>+</sup>) and product 2 ( $[M + H]^+ m/z^+ \sim 785.5033]^+$  and [M + H - $H_2O^{\dagger} m/z^+ \sim 767.4947^{\dagger}$  confirmed that these products were monoglucoside and diglucoside derivatives of PPD (C<sub>30</sub>H<sub>52</sub>O<sub>3</sub>, calculated molecular weight,  $[M + H]^+ m/z^+ \sim 461.3989)$ (Figure 2B). Microbial UGTs are usually more flexible than plant-derived UGTs toward both the sugar donors and aglycon acceptors.<sup>34</sup> Thus, various reactions by incubating PPD with UDP-Gal, UDP-GlcA, and UDP-GlcNAc were also performed; however, no new products were obtained (data not shown). Thus, Bs-YjiC can distinguish the sugar moiety of UDP-sugars.



**Figure 2.** HPLC-ESI-MS analysis of the glycosylated products of PPD. (A) HPLC chromatograms of ginsenoside standards and Bs-YjiC-catalyzed reactant. (B) MS spectra for products 1 (i) and 2 (ii).

Products 1 and 2 were purified using preparative HPLC. Their structures were confirmed by 1D NMR (<sup>1</sup>H NMR and <sup>13</sup>C NMR) and 2D NMR (HMBC, HSQC, and COSY) spectrometry (Supporting Information, Figures S2-S11). The <sup>1</sup>H and <sup>13</sup>C NMR spectra of product 1 were consistent with those of Rh2 (Table S1). The observation of significant downfield  $^{13}$ C shift (~8 ppm, "glycosylation shift") of the C3 carbon confirmed that a glucosyl moiety was attached to the C3-OH of PPD.<sup>7,15</sup> Furthermore, detailed HMBC correlations among the C3 of PPD and the anomeric proton of the glucosyl moiety, as well as the large anomeric proton-coupling constant  $(\delta_{\rm H} 4.14, J = 7.7 \text{ Hz})$ , indicated that product 1 was the 3-O- $\beta$ glucoside, thereby confirming an inverting mechanism of Bs-YjiC. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of product 2 were highly similar to those of product 1 (Table S2). A notably significant downfield <sup>13</sup>C-shift ("glycosylation shift") at  $\delta$  90.86 (~12 ppm, C3) and  $\delta$  79.66 (~9 ppm, C12) indicated that a glucosyl moiety was attached to the C3-OH and C12-OH of PPD, respectively. In the HMBC, long-range correlations between C3 of the PPD backbone and C1' and C12 of the PPD backbone and C1" further confirmed that product 2 was  $3,12-O-\beta$ diglucoside of PPD (an unnatural ginsenoside named F12 in this study). The coupling constants (J = 8.0 Hz) of the anomeric protons indicated that both of the glucosyl moieties of ginsenoside F12 adopted the  $\beta$ -configuration. Thus, Bs-YjiC can glycosylate both the C3-OH and C12-OH of PPD and PPD-type ginsenosides with regio- and stereospecificity. Furthermore, the absence of ginsenoside CK or F2 in Bs-YjiC-catalyzed reactants using PPD as an acceptor indicated that Bs-YjiC could not glycosylate the free C20-OH of PPD or ginsenoside Rh2 (Figure 2). Only ginseonosides Rh2 and F12 were detected; however,  $12-O-\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol was not observed in the Bs-YjiC-catalyzed reaction mixture (Figure 2). These results indicated that ginsenoside F12 was a C12-glycosylation product of ginsenoside Rh2. UGT109A1 was recently isolated from B. subtilis CTCC 63501.<sup>14</sup> The deduced amino acid sequences of UGT109A1 exhibited 94% identity with those of Bs-YjiC; however, UGT109A1 could glycosylate the free C3-OH and C12-OH of PPD to synthesize ginsenoside Rh2,  $12-O-\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol, and ginsenoside F12. Thus, further studies should be performed to determine the key amino acids of Bs-YjiC involved in the regiospecific glycosylation of PPD and to the synthesize a specific ginsenoside (e.g., ginsenoside Rh2 or  $12-O-\beta$ -D-glucopyrano-syl-20(S)-protopanaxadiol) using an engineered Bs-YjiC.

The  $K_{\rm m}$  values of Bs-YjiC for PPD and ginsenoside Rh2 were 163.00 and 139.50  $\mu$ M, respectively (Figure S12) (Table 1).

Table 1. Kinetic Parameters of Bs-YjiC toward PPD and Ginsenoside Rh2

substrate	$K_{\rm m}~(\mu{\rm M})$	$k_{\rm cat}~({\rm s}^{-1})$	$k_{\rm cat}/K_{\rm m}({\rm s}^{-1}~{\rm M}^{-1})$
PPD	$163.00 \pm 16.76$	$1.31 \pm 0.04$	$0.34 \times 10^{4}$
Rh2	$139.50 \pm 21.09$	$5.68 \pm 0.27$	$4.07 \times 10^{4}$

The K<sub>m</sub> values of Bs-YjiC for PPD and ginsenoside Rh2 were compared with those of other UGTs involved in the biosynthesis of ginsenosides.<sup>10,14,15,17</sup> Nevertheless, the  $k_{cat}$ values of Bs-YjiC for PPD (1.31 s<sup>-1</sup>) and Rh2 (5.68 s<sup>-1</sup> were considerably high, thereby resulting in a higher catalytic efficiency (0.34  $\times$  10<sup>4</sup> s<sup>-1</sup> M<sup>-1</sup> for PPD and 4.07  $\times$  10<sup>4</sup> s<sup>-1</sup> M<sup>-1</sup> for ginsenoside Rh2) than those of PgUGT74AE2 from P. ginseng and engineered UGT51 from S. cerevisiae.<sup>15,17</sup> The high catalytic efficiencies of Bs-YjiC toward PPD and ginsenoside Rh2 and its remarkable acceptor plasticity were in agreement with the previous notion that naturally occurring UGTs with high catalytic proficiencies generally show broad acceptor tolerance.<sup>30,35</sup> In addition, the higher catalytic efficiency of Bs-YjiC toward ginsenoside Rh2 than toward PPD was consistent with the results in which ginsenoside F12 was the major product when PPD was used as the substrate, and F12 was synthesized via a continuous two-step glycosylation of PPD.

In Vitro Cytotoxicity of Ginsenoside F12. Glycosylation of C3-OH and/or C20-OH of PPD considerably influences the pharmacological properties of PPD-type ginsenosides.<sup>10</sup> Ginsenoside F12 synthesized by UGT109A1was recently found to have higher effectiveness against NCI-H460 lung cancer cells than that of ginsenoside Rg3.14 In the present study, the bioactivity of ginsenoside F12 was further evaluated using Lovo colon cancer cells, DMS53 lung cancer cells, HepG2 liver cancer cells, and SNU719 gastric cancer cells, which were compared with the most active ginsenosides, ginsenosides Rh2 and Rg3. Ginsenoside F12 can inhibit the proliferation of Lovo colon cancer cells, HepG2 liver cancer cells, DMS53 lung cancer cells, and SNU719 gastric cancer cells with IC<sub>50</sub> values of 49.2, 58.8, 55.9, and 44.8  $\mu$ M, respectively (Table 2). Although both ginsenosides Rg3 and F12 were diglucoside derivatives of PPD, the in vitro cytotoxicity of ginsenoside F12 against cancer cell lines was much higher than that of ginsenoside Rg3. These results indicated that the position of glucosyl moieties attached to PPD remarkably influenced the anticancer activities of PPD-type ginsenosides. Notably, ginsenoside F12 exhibited the highest cytotoxicity against DMS53 lung cancer cells, with an IC<sub>50</sub> of 55.9  $\mu$ M, whereas the IC<sub>50</sub> values of ginsenosides Rh2 and Rg3 against DMS53 lung cancer cells were 107.5 and >400  $\mu$ M, respectively. However, ginsenoside Rh2 was still the most active ginsenoside against Lovo colon cancer cells, HepG2 liver cancer cells, and SNU719 gastric cancer cells, with IC<sub>50</sub> values of 24.1, 23.3, and 12.0  $\mu$ M, respectively. The present study was consistent with previous findings that ginsenosides with a low

	/ / / / /					
compound	Lovo <sup>a</sup>	HepG2 <sup>b</sup>	DMS53 <sup>c</sup>	SNU719 <sup>d</sup>		
Rg3	>400	$364.1 \pm 20.2$	>400	$359.4 \pm 30.1$		
Rh2	$24.1 \pm 1.5$	$23.3 \pm 1.8$	$107.5 \pm 10.5$	$12.0 \pm 0.6$		
F12	$49.2 \pm 4.4$	$58.8 \pm 3.9$	$55.9 \pm 3.2$	$44.8 \pm 2.8$		
<sup>*</sup> Lovo, colon cancer cells. <sup>b</sup> HepG2, liver cancer cells. <sup>c</sup> DMS53, lung cancer cells. <sup>d</sup> SNU719, gastric carcinoma cells.						

Table 2. Cancer Cell Line Cytotoxicity  $(\mu M)$ 

degree of glycosylation show stronger inhibitory activity against cancer cells than ginsenosides bearing more sugar moieties.<sup>36</sup>

**Glycosylation of PPD-Type Ginsenosides with Bs-YjiC.** We were interested in the glycosylation of other PPD-type ginsenosides using Bs-YjiC. Thus, the reactions of PPD-type ginsenosides, including ginsenosides Rh2, CK, F2, Rg3, and Rd, were carried out under conditions that were identical to those of PPD (Figure 3). With ginsenoside Rh2, only one diglucoside



Figure 3. HPLC analysis of the glycosylated products of ginsenosides Rh2, CK, F2, Rg3, and Rd catalyzed by Bs-YjiC.

(product 3,  $[M + H]^+ m/z^+ \sim 785.5042$ ) with the same retention time ( $t_{\rm R}$  = 17.1 min) as that of F12 was produced, as confirmed by HPLC-ESI-MS (Figure S13). Product 3 should be ginsenoside F12 because Bs-YjiC catalyzed a continuous two-step glycosylation reaction of PPD (Figure 1). With ginsenoside CK containing the free C3-OH and C12-OH, one diglucoside (product 4,  $t_{\rm R}$  = 15.9 min,  $[M + H]^+ m/z^+$ ~785.5017) and one triglucoside (product 5,  $t_{\rm R}$  = 13.9 min,  $[M + H]^+ m/z^+ \sim 947.5689$ ) were confirmed by HPLC-ESI-MS (Figure S14). Considering that Bs-YjiC could only glycosylate the free C3-OH and C12-OH of PPD and the  $t_{\rm R}$  of product 4 was identical with that of ginsenoside F2, we speculated that product 4 should be ginsenoside F2 (Figure 1). For ginsenoside F2, which only contained a free C12-OH, only one triglucoside (product 6,  $t_{\rm R}$  = 13.9 min,  $[M + H]^+ m/z^+ \sim 947.5655$ ) was detected (Figure S15). Notably, the  $t_{\rm R}$  values of products 5 and 6 were identical to each other and were not consistent with those of Rd. Thus, we speculated that products 5 and 6 should

be the same derivative of F2 with an additional glucosyl moiety attached to the free C12-OH, namely,  $3-O-\beta$ -D-glucopyranosyl-12- $O-\beta$ -D-glucopyranosyl-20- $O-\beta$ -D-glucopyranosyl-20(S)-protopanaxadiol (Figure 1). With ginsenosides Rg3 and Rd, which only contained a free C12-OH, only one new glucoside was detected in each reaction mixtures, as follows: product 7 ( $t_{\rm R}$  = 12.6 min,  $[M + H]^+ m/z^+ \sim 947.5639$  and product 8 ( $t_R = 11.8$ min,  $[M + H]^+ m/z^+ \sim 1109.6080)$  (Figures S16 and S17). Based on the regiospecificity of Bs-YjiC toward PPD and the speculated glycosylation patterns of Bs-YjiC toward ginsenosides Rh2, CK, and F2, products 7 and 8 should be novel unnatural ginsenosides with an additional glucosyl moiety attached to the free C12-OH of ginsenosides Rg3 and Rd, respectively (Figure 1). Considering that glycosylation is the prominent biological mechanism for the structural and functional diversity of ginsenosides, the unnatural PPD-type ginsenosides 5 or 6, 7, 8, and 9 with a glucosyl moiety attached to the C12-OH might have various novel biological and pharmacological activities that are similar to those of ginsenoside F12 and other PPD-type ginsenosides.<sup>36</sup>

**Optimizing the Parameters for One-Pot Synthesis of Ginsenosides Rh2 and F12.** An engineered yeast cell factory that can produce substantial amounts of PPD has been constructed in our previous study, which makes PPD a widely available precursor for the biosynthesis of PPD-type ginsenosides.<sup>11</sup> The high expression level and catalytic efficiency of Bs-YjiC toward PPD suggested that Bs-YjiC was a promising biocatalyst for industrial applications. Thus, the *AtSuSy* gene was amplified from the cDNA of *A. thaliana* and heterologously expressed in *E. coli* BL21 (DE3) as that of Bs-YjiC (Figure S1). A one-pot cascade reaction by coupling Bs-YjiC to AtSuSy was established to create an in situ UDPG regeneration and was applied to synthesize ginsenosides Rh2 and F12 with PPD and sucrose as the aglycon and sugar donor, respectively.

PPD could be transformed into ginsenosides Rh2 and F12 through a Bs-YjiC-AtSuSy cascade reaction as an enzymatic approach using UDPG as the sugar donor (Figure S18). This reaction revealed that AtSuSy could effectively synthesize UDPG. To determine the optimal reaction conditions, the effects of ratios of Bs-YjiC and AtSuSy on the one-pot synthesis of ginsenosides Rh2 and F12 were initially determined (Table 3). Ginsenoside F12 production increased by 237% when increasing the amount of Bs-YjiC from 40 mU mL<sup>-1</sup> to 160 mU mL<sup>-1</sup>; however, only a trace amount of ginsenoside Rh2 (~0.04 mM) was detected, which was similar to the Bs-YjiC-catalyzed reaction using UDPG as the sugar donor. When the amount of AtSuSy was increased from 50 mU  $mL^{-1}$  to 200 mU  $mL^{-1}$ , ginsenoside F12 production was increased by 373%, whereas ginsenoside Rh2 was decreased from 0.11 mM to 0.05 mM. The molar ratios of ginsenoside Rh2/ginsenoside F12 decreased from 0.58 to 0.08 when the amount of AtSuSy was increased from 50 mU mL<sup>-1</sup> to 200 mU mL<sup>-1</sup>. Considering that AtSuSy was responsible for the formation of UDPG, the present study suggested that ginsenoside Rh2 was favorably produced in the presence of limited UDP-glucose concen-

Table 3. Optimization of the Enzyme Concentrations for the Bs-YjiC/AtSuSy Cascade Reaction

	Bs-YjiC	AtSuSy	F12	Rh2
entry	(mU/mL)	(mU/mL)	(mM)	(mM)
1	40	200	0.27	0.04
2	80	200	0.41	0.04
3	160	200	0.64	0.05
4	320	200	0.72	0.05
5	160	50	0.19	0.11
6	160	100	0.36	0.12
7	160	200	0.63	0.05
8	160	300	0.71	0.04

trations and further reconfirmed that ginsenoside F12 was a C12-glycosylation product of ginsenoside Rh2. Ginsenoside F12 production increased slightly ( $\sim$ 13%) when the amount of Bs-YjiC or AtSuSy was doubled. Thus, the optimal ratio of Bs-YjiC and AtSuSy was 160:200 mU mL<sup>-1</sup>.

The conversion rates of PPD were determined with different pH values (pH 6.0–8.5), temperatures (30–45 °C), DMSO (0–20%), UDP (0.05–0.3 mM), sucrose (0.2–1 M), and PPD (0.5–2 mM) to further determine the optimal reaction conditions (Figure 4). The highest conversion of PPD was



Figure 4. Optimization of the reaction conditions for the Bs-YjiC/AtSuSy cascade reaction.

achieved at 40 °C and pH 8.0 (Figure 4a and b). Although the poor solubility of hydrophobic PPD can remarkably inhibit Bs-YjiC-catalyzed reaction and the addition of DMSO can significantly improve the availability of PPD in the reaction system, the conversions of PPD were slightly increased when DMSO was increased from 0% to 5%. When the concentration of DMSO exceeded 10%, the conversion of PPD rapidly decreased, and only 32% of PPD was glycosylated in the presence of 20% DMSO (Figure 4c). UDP is the most expensive cofactor in the UGT-SuSy reaction mixtures and has intricate effects on the UGT-SuSy reaction due to its importance during the formation of PPD increased by 2.3-fold

when the concentration of UDP was increased from 0.05 mM to 0.2 mM and was slightly increased when the concentration of UDP continued to increase (Figure 4d). The highest conversion of PPD was observed in the presence of 0.4 M sucrose and was slightly changed when the concentration of sucrose continued to increase (Figure 4e). The conversion of PPD was decreased from 98% to 32% when the concentration of PPD was increased from 0.5 mM to 2 mM, and maximal ginsenoside F12 production (0.67 mM) was obtained in the presence of 1.0 mM PPD (Figure 4f). In summary, 40 °C, pH 8.0, 5% DMSO, 0.2 mM UDP, 0.4 M sucrose, and 1.0 mM PPD were used for the fed-batch reaction.

**One-Pot Synthesis of Ginsenosides Rh2 and F12 by Fed-Batch Reaction.** Based on the optimal parameters presented above, a fed-batch reaction by periodic addition of PPD was conducted to avoid the inhibition of a high concentration of PPD. As shown in Figure 5, the glycosylation



Figure 5. One-pot synthesis of ginsenosides Rh2 and F12 by fed-batch reaction. One mM PPD was added to the reaction mixtures at 1, 2, 4, 6, and 8 h. Fresh enzymes (160 mU mL<sup>-1</sup> Bs-YjiC and 200 mU mL<sup>-1</sup> AtSuSy) were added at 6 h.

of PPD was relatively fast, and 1 mM PPD could be completely converted into 0.02 mM ginsenoside Rh2 and 0.92 mM F12 in 1 h (Figure 5). Only a trace amount of ginsenoside Rh2 was detected in the first 3 h, and ginsenoside F12 was the major product, which was consistent with the in vitro enzymatic reaction using UDPG as the glucosyl donor. Nevertheless, the molar ratios of ginsenosides Rh2/F12 increased with the extension of reaction times. After 12 h, 0.32 mM (0.20 g  $L^{-1}$ ) ginsenoside Rh2 and 5.07 mM ginsenoside F12 ( $3.98 \text{ g L}^{-1}$ ) were obtained through the periodic feeding of PPD with the conversion of PPD by 90%. A maximum number of 27.0 was obtained for the UDPG regeneration cycles. To the best of our knowledge, the titer of ginsenoside F12 produced in the present study was much higher than those of other PPD-type ginsenosides synthesized by yeast cell factories.<sup>14,16,17,37</sup> This is the first report for biosynthesis of triterpene saponins using the UGT-SuSy cascade system. Considering that a PPD-producing yeast cell factory can produce substantial amounts of PPD,<sup>11</sup> an in vitro UGT-SuSy cascade reaction could be exploited as a novel promising alternative for semisynthesis of highly valuable PPD-type ginsenosides by using PPD as the precursor.

In summary, Bs-YjiC from *B. subtilis* 168 can regio- and stereospecifically transfer a glucosyl moiety to the free C3-OH and C12-OH of PPD and PPD-type ginsenosides to synthesize natural and unnatural PPD-type ginsenosides. These findings provided insights into the important roles of microbial UGTs for the biosynthesis of ginsenosides. This study suggested that the in vitro UGT-SuSy cascade reaction could be exploited as an effective approach for biosynthesis of ginsenosides. In vivo and in vitro biological activities of ginsenosides F12 and other unnatural ginsenosides synthesized in this study should be investigated in future studies.

#### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jafc.8b00597.

<sup>1</sup>H and <sup>13</sup>C NMR spectral data for products 1 and 2 (Tables S1 and S2), some experimental results (Figures S1, S2, and S18), and HPLC-Q-TOF/ESI-MS and NMR analysis (Figures S2–S17) (PDF)

# AUTHOR INFORMATION

# **Corresponding Authors**

\*E-mail (X. Zhang): zhang\_xl@tib.cas.cn. Tel: +862284861983.

\*E-mail (Y. Sun): sun\_yx@tib.cas.cn. Tel: +862284861960.

## ORCID <sup>©</sup>

Longhai Dai: 0000-0001-5662-9252 Caixia Dong: 0000-0002-4749-9510 Jiangang Yang: 0000-0001-9463-8862

# Author Contributions

<sup>⊥</sup>L. Dai and C. Liu contributed equally to this work.

#### Funding

This work was supported by the National Natural Science Foundation of China (no. 21702226), the Key Research Program of the Chinese Academy of Sciences (no. KFZD-SW-215), and the Technology Planning Project of Tianjin (no. 16YFXTNC00160).

#### Notes

The authors declare no competing financial interest.

# REFERENCES

(1) Choi, J.; Choi, T.; Lee, M.; Kim, T. Ginseng for Health Care: A Systematic Review of Randomized Controlled Trials in Korean Literature. *PLoS One* **2013**, *8*, 697–702.

(2) Dong, W. W.; Xuan, F. L.; Zhong, F. L.; Jiang, J.; Wu, S.; Li, D.; Quan, L. H. Comparative Analysis of the Rats' Gut Microbiota Composition in Animals with Different Ginsenosides Metabolizing Activity. J. Agric. Food Chem. **2016**, 65, 327.

(3) Kang, A.; Xie, T.; Zhu, D.; Shan, J.; Di, L.; Zheng, X. Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. *J. Agric. Food Chem.* **2017**, *65*, 6861–6869.

(4) Wang, Z.; Hu, J.; Yan, M.; Xing, J.; Liu, W.; Li, W. Caspasemediated anti-apoptotic effect of Ginsenoside Rg5, a main rare ginsenoside, on Acetaminophen-induced Hepatotoxicity in Mice. J. Agric. Food Chem. 2017, 65, 9226.

(5) Dai, Z.; Wang, B.; Liu, Y.; Shi, M.; Wang, D.; Zhang, X.; Liu, T.; Huang, L.; Zhang, X. Producing aglycons of ginsenosides in bakers' yeast. *Sci. Rep.* **2015**, *4*, 3698.

(6) Li, L.; Shin, S. Y.; Lee, S. J.; Moon, J. S.; Im, W. T.; Han, N. S. Production of ginsenoside F2 by using *Lactococcus lactis* with enhanced expression of  $\beta$ -glucosidase gene from *Paenibacillus mucilaginosus. J. Agric. Food Chem.* **2016**, *64*, 2506.

(7) Pei, J.; Xie, J.; Yin, R.; Zhao, L.; Ding, G.; Wang, Z.; Xiao, W. Enzymatic transformation of ginsenoside Rb1 to ginsenoside 20(S)-Rg3 by GH3  $\beta$ -glucosidase from *Thermotoga thermarum* DSM 5069 T. *J. Mol. Catal.* B: Enzym. **2015**, 113, 104–109. (8) Seo, J. Y.; Ju, S. H.; Oh, J.; Lee, S. K.; Kim, J. S. Neuroprotective and Cognition Enhancing Effects of Compound K Isolated from Red Ginseng. J. Agric. Food Chem. 2016, 64, 2855–2864.

(9) Wang, C.; He, H.; Dou, G.; Li, J.; Zhang, X.; Jiang, M.; Li, P.; Huang, X.; Chen, H.; Li, L. Ginsenoside 20(S)-Rh2 Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells: Role of Orphan Nuclear Receptor Nur77. *J. Agric. Food Chem.* **2017**, *64*, 7687–7697. (10) Jung, S. C.; Kim, W.; Park, S. C.; Jeong, J.; Park, M. K.; Lim, S.; Lee, Y.; Im, W. T.; Lee, J. H.; Choi, G. Two ginseng UDPglycosyltransferases synthesize ginsenoside Rg3 and Rd. *Plant Cell Physiol.* **2014**, *55*, 2177–88.

(11) Dai, Z.; Liu, Y.; Zhang, X.; Shi, M.; Wang, B.; Wang, D.; Huang, L.; Zhang, X. Metabolic engineering of *Saccharomyces cerevisiae* for production of ginsenosides. *Metab. Eng.* **2013**, *20*, 146–156.

(12) Han, J. Y.; Kim, H. J.; Kwon, Y. S.; Choi, Y. E. The Cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in *Panax ginseng*. *Plant Cell Physiol.* **2011**, *52*, 2062–73.

(13) Han, J. Y.; Kwon, Y. S.; Yang, D. C.; Jung, Y. R.; Choi, Y. E. Expression and RNA interference-induced silencing of the dammarenediol synthase gene in *Panax ginseng*. *Plant Cell Physiol.* **2006**, *47*, 1653–62.

(14) Liang, H.; Hu, Z.; Zhang, T.; Gong, T.; Chen, J.; Zhu, P.; Li, Y.; Yang, J. Production of a bioactive unnatural ginsenoside by metabolically engineered yeasts based on a new UDP-glycosyltransferase from *Bacillus subtilis. Metab. Eng.* **2017**, *44*, 60–69.

(15) Wang, P.; Wei, Y.; Yun, F.; Liu, Q.; Wei, W.; Yang, C.; Lei, Z.; Zhao, G.; Yue, J.; Xing, Y. Production of bioactive ginsenosides Rh2 and Rg3 by metabolically engineered yeasts. *Metab. Eng.* **2015**, *29*, 97–105.

(16) Yan, X.; Fan, Y.; Wei, W.; Wang, P.; Liu, Q.; Wei, Y.; Zhang, L.; Zhao, G.; Yue, J.; Zhou, Z. Production of bioactive ginsenoside compound K in metabolically engineered yeast. *Cell Res.* **2014**, *24*, 770–3.

(17) Zhuang, Y.; Yang, G.-Y.; Chen, X.; Liu, Q.; Zhang, X.; Deng, Z.; Feng, Y. Biosynthesis of plant-derived ginsenoside Rh2 in yeast via repurposing a key promiscuous microbial enzyme. *Metab. Eng.* **2017**, *42*, 25–32.

(18) Atopkina, L. N.; Malinovskaya, G. V.; Elyakov, G. B.; Uvarova, N. I.; Woerdenbag, H. J.; Koulman, A.; Pras, N.; Potier, P. Cytotoxicity of natural ginseng glycosides and semisynthetic analogues. *Planta Med.* **1999**, *65*, 30–34.

(19) Gutmann, A.; Lepak, A.; Diricks, M.; Desmet, T.; Nidetzky, B. Glycosyltransferase cascades for natural product glycosylation: Use of plant instead of bacterial sucrose synthases improves the UDP-glucose recycling from sucrose and UDP. *Biotechnol. J.* **2017**, *12*, 1600557.

(20) Schmölzer, K.; Gutmann, A.; Diricks, M.; Desmet, T.; Nidetzky, B. Sucrose synthase: A unique glycosyltransferase for biocatalytic glycosylation process development. *Biotechnol. Adv.* **2015**, *34*, 88–111.

(21) Schmölzer, K.; Lemmerer, M.; Gutmann, A.; Nidetzky, B. Integrated process design for biocatalytic synthesis by a Leloir glycosyltransferase: UDP-glucose production with sucrose synthase. *Biotechnol. Bioeng.* **2017**, *114*, 924–928.

(22) Dewitte, G.; Walmagh, M.; Diricks, M.; Lepak, A.; Gutmann, A.; Nidetzky, B.; Desmet, T. Screening of recombinant glycosyltransferases reveals the broad acceptor specificity of stevia UGT-76G1. *J. Biotechnol.* **2016**, 233, 49–55.

(23) Gutmann, A.; Nidetzky, B. Unlocking the Potential of Leloir Glycosyltransferases for Applied Biocatalysis: Efficient Synthesis of Uridine 5'-Diphosphate-Glucose by Sucrose Synthase. *Adv. Synth. Catal.* **2016**, *358*, 3600–3609.

(24) Chiu, H. H.; Shen, M. Y.; Liu, Y. T.; Fu, Y. L.; Chiu, Y. A.; Chen, Y. H.; Huang, C. P.; Li, Y. K. Diversity of sugar acceptor of glycosyltransferase 1 from *Bacillus cereus* and its application for glucoside synthesis. *Appl. Microbiol. Biotechnol.* **2016**, *100*, 1–13.

(25) Gantt, R. W.; Goff, R. D.; Williams, G. J.; Thorson, J. S. Probing the Aglycon Promiscuity of an Engineered Glycosyltransferase. *Angew. Chem., Int. Ed.* **2008**, *47*, 8889–92. (26) Pandey, R. P.; Parajuli, P.; Koirala, N.; Park, J. W.; Sohng, J. K. Probing 3-hydroxyflavone for in vitro glycorandomization of flavonols by YjiC. *Appl. Environ. Microbiol.* **2013**, *79*, 6833–8.

(27) Pandey, R. P.; Tai, F. L.; Kim, E. H.; Yamaguchi, T.; Yong, I. P.; Kim, J. S.; Sohng, J. K. Enzymatic Synthesis of Novel Phloretin Glucosides. *Appl. Environ. Microbiol.* **2013**, *79*, 3516–21.

(28) Zhou, M.; Hou, Y.; Hamza, A.; Pain, C.; Zhan, C. G.; Bugni, T. S.; Thorson, J. S. Probing the regiospecificity of enzyme-catalyzed steroid glycosylation. *Org. Lett.* **2012**, *14*, 5424–7.

(29) Bo, F.; Chen, T.; Zhang, S.; Wu, B.; He, B. Mining of efficient microbial UDP-glycosyltransferases by motif evolution cross plant kingdom for application in biosynthesis of salidroside. *Sci. Rep.* **2017**, 7, 463.

(30) Dai, L.; Li, J.; Yao, P.; Zhu, Y.; Men, Y.; Zeng, Y.; Yang, J.; Sun, Y. Exploiting the aglycon promiscuity of glycosyltransferase Bs-YjiC from *Bacillus subtilis* and its application in synthesis of glycosides. *J. Biotechnol.* **2017**, *248*, 69–76.

(31) Dai, L.; Li, J.; Yang, J.; Zhu, Y.; Men, Y.; Zeng, Y.; Cai, Y.; Dong, C.; Dai, Z.; Zhang, X.; Sun, Y. Promiscuous glycosyltransferase from *Bacillus subtilis* 168 for the enzymatic synthesis of novel protopanaxatriol-type ginsenosides. *J. Agric. Food Chem.* **2018**, *66*, 943.

(32) Dai, L.; Liu, C.; Zhu, Y.; Zhang, J.; Men, Y.; Zeng, Y.; Sun, Y. Functional Characterization of Cucurbitadienol Synthase and Triterpene Glycosyltransferase Involved in Biosynthesis of Mogrosides from *Siraitia grosvenorii*. *Plant Cell Physiol.* **2015**, *56*, 1172.

(33) Liu, C.; Zeng, Y.; Dai, L. H.; Cai, T. Y.; Zhu, Y. M.; Dou, D. Q.; Ma, L. Q.; Sun, Y. X. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. *Am. J. Cancer Res.* **2015**, *5*, 1308.

(34) Song, M. C.; Kim, E.; Ban, Y. H.; Yoo, Y. J.; Kim, E. J.; Park, S. R.; Pandey, R. P.; Sohng, J. K.; Yoon, Y. J. Achievements and impacts of glycosylation reactions involved in natural product biosynthesis in prokaryotes. *Appl. Microbiol. Biotechnol.* **2013**, *97*, 5691–704.

(35) Oberthür, M.; Leimkuhler, C.; Kruger, R. G.; Lu, W.; Walsh, C. T.; Kahne, D. A systematic investigation of the synthetic utility of glycopeptide glycosyltransferases. *J. Am. Chem. Soc.* **2005**, *127*, 10747–10752.

(36) Park, C.-S.; Yoo, M.-H.; Noh, K.-H.; Oh, D.-K. Biotransformation of ginsenosides by hydrolyzing the sugar moieties of ginsenosides using microbial glycosidases. *Appl. Microbiol. Biotechnol.* **2010**, *87*, 9– 19.

(37) Wei, W.; Wang, P.; Wei, Y.; Liu, Q.; Yang, C.; Zhao, G.; Yue, J. Characterization of *Panax ginseng* UDP-Glycosyltransferases Catalyzing Protopanaxatriol and Biosyntheses of Bioactive Ginsenosides F1 and Rh1 in Metabolically Engineered Yeasts. *Mol. Plant* **2015**, *8*, 1412–1424.